Sanofi and Regeneron Report Positive Results of Dupixent (dupilumab) in P-IIIa Dupixent Eosinophilic Esophagitis Study for EoE
Shots:
- The P-IIIa Dupixent Eosinophilic Esophagitis study involves assessing Dupixent (N=42) (300mg weekly) v/s PBO (N=39) in 81 patients aged 12 years and older with eosinophilic esophagitis (EoE). In addition- enrolling patients for P-IIIb for extended active treatment period to continue in 28wks
- The P-II study results: met its co-1EPs and 2EPs in DSQ baseline with reduction in disease symptoms (69% vs 32%)- EoE count reduction (60% vs 5%)
- Dupixent is a mAb to inhibit the signaling of IL-4 and IL-13 proteins and has received US FDA’s Orphan Drug Designation to treat EoE in 2017
Click here to read full press release/ article | Ref: Sanofi | Image: Behance
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com